IceCure Medical (NASDAQ:ICCM) and Nanovibronix (NASDAQ:FEED) Critical Comparison

Nanovibronix (NASDAQ:FEED) and IceCure Medical (NASDAQ:ICCM) are both small-cap healthcare companies, but which is the better investment? We will contrast the two businesses based on the strength of their dividends, profitability, risk, earnings, analyst recommendations, institutional ownership and valuation.

Analyst Ratings

This is a breakdown of current ratings and recommmendations for Nanovibronix and IceCure Medical, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Nanovibronix	1	0	0	0	1.00
IceCure Medical	2	0	3	0	2.20

IceCure Medical has a consensus target price of $52.50, indicating a potential upside of 2,592.31%. Given IceCure Medical’s stronger consensus rating and higher possible upside, analysts plainly believe IceCure Medical is more favorable than Nanovibronix.

Insider & Institutional Ownership

16.4% of Nanovibronix shares are owned by institutional investors. Comparatively, 0.6% of IceCure Medical shares are owned by institutional investors. 12.2% of Nanovibronix shares are owned by company insiders. Comparatively, 2.4% of IceCure Medical shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Earnings & Valuation

This table compares Nanovibronix and IceCure Medical”s gross revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Nanovibronix	$1.93 million	0.26	-$18.18 million	($117.28)	-0.00
IceCure Medical	$3.38 million	1.98	-$15.06 million	($8.52)	-0.23

IceCure Medical has higher revenue and earnings than Nanovibronix. IceCure Medical is trading at a lower price-to-earnings ratio than Nanovibronix, indicating that it is currently the more affordable of the two stocks.

Risk & Volatility

Nanovibronix has a beta of 1.38, meaning that its share price is 38% more volatile than the S&P 500. Comparatively, IceCure Medical has a beta of 0.45, meaning that its share price is 55% less volatile than the S&P 500.

Profitability

This table compares Nanovibronix and IceCure Medical’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Nanovibronix	-1,093.61%	-60.73%	-48.48%
IceCure Medical	-427.67%	-174.26%	-112.58%

Summary

IceCure Medical beats Nanovibronix on 8 of the 14 factors compared between the two stocks.

About Nanovibronix

NanoVibronix Inc. is a medical device company that is focused on creating medical products utilizing its proprietary low-intensity, surface acoustic wave technology. … NanoVibronix’ catheter-based products include the UroShield™ and NG-Shield™ devices that are both CE mark certified.

About IceCure Medical

IceCure Medical Ltd, a commercial stage medical device company, engages in the research, development, and marketing of cryoablation systems, disposables, and technologies for treating tumors. The company offers ProSense system, a single probe system for the treatment of tumors, as well as associated disposables; and IceSense3 system for ablation indications to urology, oncology, dermatology, gynecology, general surgery, thoracic surgery, and proctology. It also develops XSense system, a single probe system; and MultiSense, a multi probe system for the treatment of multiple and larger tumors. The company was incorporated in 2006 and is headquartered in Caesarea, Israel.